Tamsulosin

From Wikipedia, the free encyclopedia

Chemical structure of Tamsulosin
Tamsulosin
Systematic (IUPAC) name
(R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-
2-methoxybenzenesulfonamide
Identifiers
CAS number 106133-20-4
ATC code G04CA02
PubChem 129211
DrugBank APRD00036
Chemical data
Formula C20H28N2O5S 
Mol. mass 408.51
Pharmacokinetic data
Bioavailability 100% (oral)
Metabolism hepatic
Half life 9–13 hours
Excretion 76% renal
Therapeutic considerations
Pregnancy cat.

B2 (Aust)

Legal status

Schedule 4 (Aust)
POM (UK)

Routes oral

Tamsulosin (rINN) (IPA: [tæmˈsulosɪn, tæmsuˈlosɪn, ]) is an α1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH). Tamsulosin was developed by Yamanouchi Pharmaceuticals (now part of Astellas Pharma) and is marketed by various companies under licence, including Boehringer-Ingelheim and CSL. As of 2006, tamsulosin hydrochloride extended-release tablets are marketed under the trade name Flomaxtra. It was formerly marketed as modified-release capsules under the trade name Flomax.

Contents

[edit] Clinical use

[edit] Adverse effects

Two ADRs (Adverse Drug Reactions) have been reported:

  • Immunologic: It contains a sulfa moiety, thus causing typical reactions to sulfa drugs.
  • Ophthalmologic: It causes complications during cataract surgery.

[edit] Clinical comparison

Although prostate specific, it does not have the prostate apoptotic effects of other alpha-blockers such as doxazosin and terazosin.

[edit] External links

In other languages